GLPwatch

Combination Therapy With Semaglutide and Dapagliflozin as an Effective Approach for the Management of Type A Insulin Resistance Syndrome: A Case Report.

Front Endocrinol (Lausanne) · 2022

Last updated 2026-05-28

A patient with a rare genetic disorder called Type A insulin resistance syndrome, which causes severe insulin resistance and diabetes without obesity, was treated with a combination of two diabetes medications: semaglutide (a GLP-1 drug) and dapagliflozin (an SGLT2 inhibitor). This is the first reported case of using these two drugs together for this condition.

AI summary of the abstract below.

JournalFront Endocrinol (Lausanne), 2022
Citations5
Relative citation ratio0.53
NIH percentile31
Molecules semaglutide
Conditions studied Type 2 Diabetes

Abstract

Type A insulin resistance (IR) syndrome is a very uncommon genetic disorder affecting the insulin receptor (INSR) gene, characterized by severe IR without the presence of obesity. Patients with this condition will eventually develop diabetes, presenting a variable response to insulin-sensitizers, such as metformin and thiazolidinediones, and high doses of insulin. We report for the first time the results of the use of combination therapy with a glucagon-like peptide-1 receptor agonist and a sodium-glucose cotransporter 2 inhibitor for the treatment of diabetes in the context of type A IR syndrome.

Verbatim abstract via PubMed 35498407 ↗

Related research